{"gene":"ARID3A","run_date":"2026-04-28T17:12:37","timeline":{"discoveries":[{"year":2006,"finding":"ARID3A (Bright) directly interacts with TFII-I through amino acids in Bright's protein interaction domain, and specific tyrosine residues of TFII-I (phosphorylated by Bruton's tyrosine kinase, Btk) are essential for Bright-induced immunoglobulin heavy-chain reporter gene activity. Inhibition of TFII-I in B cells decreased heavy-chain transcript levels, identifying a three-component complex (Bright/TFII-I/Btk) required for immunoglobulin transcription.","method":"Co-immunoprecipitation, domain-mapping interaction assays, immunoglobulin reporter gene assays, siRNA inhibition of TFII-I in B-cell lines","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 — reciprocal interaction mapping plus functional reporter assay and knockdown, moderate evidence from single lab with multiple orthogonal methods","pmids":["16738337"],"is_preprint":false},{"year":2010,"finding":"Loss of Bright/ARID3a function (via knockout mouse models or direct siRNA knockdown of human Bright) promotes developmental plasticity: Bright-deficient somatic cells expressed pluripotency-associated gene products, expanded indefinitely, and spontaneously differentiated into cells of multiple lineages, indicating Bright normally represses pluripotency.","method":"Knockout mouse models, siRNA knockdown, colony formation assays, multi-lineage differentiation assays, gene expression profiling","journal":"Stem cells (Dayton, Ohio)","confidence":"High","confidence_rationale":"Tier 2 — three independent lines of evidence including two mouse models and human cell knockdown with defined pluripotency phenotype","pmids":["20680960"],"is_preprint":false},{"year":2011,"finding":"ARID3A cooperates with p53 to transcriptionally activate p21WAF1 in response to DNA damage. ARID3A binds directly to AT-rich sites in the p21WAF1 promoter in vitro and in vivo (ChIP), and its knockdown suppressed p21WAF1 transcription after DNA damage without affecting NOXA or PUMA. Additionally, p53 and ARID3A show interdependence: p53 knockdown decreased ARID3A transcription, and ARID3A overexpression/knockdown increased/decreased p53 stability.","method":"ChIP, in vitro DNA binding, reporter gene assays, siRNA knockdown, co-expression studies in p53-positive and p53-null cell lines","journal":"Biochemical and biophysical research communications","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods (ChIP, in vitro binding, functional reporter, KD with specific phenotype) in a single study","pmids":["22172947"],"is_preprint":false},{"year":2011,"finding":"A third ARID3 family member, Brightlike/ARID3C, physically associates with ARID3A (Bright) in solution and at common DNA binding sites in vitro, and co-activates Bright-dependent IgH transcription. Brightlike undergoes nuclear-cytoplasmic shuttling dependent on the REKLES domain and localizes to lipid rafts after BCR stimulation. Sumoylation of Brightlike reduces its co-activation capacity.","method":"Co-immunoprecipitation, in vitro DNA binding, IgH reporter gene assays, nuclear-cytoplasmic fractionation, lipid raft fractionation, SUMO modification assays","journal":"Molecular immunology","confidence":"Medium","confidence_rationale":"Tier 2/3 — multiple methods from a single lab with functional reporter validation","pmids":["21955986"],"is_preprint":false},{"year":2012,"finding":"miR-125b directly targets and represses ARID3A/Bright in B-cell progenitors, and this repression blocks differentiation while conferring a survival advantage. Forced Bright/ARID3A repression in pre-BI cells mimicked miR-125b-induced differentiation blockade, increased proliferation, and inhibited apoptosis via caspase pathway inhibition independent of p53 and BAK1.","method":"miR-125b overexpression/inhibition in murine and human leukemic B-cell lines, 3'UTR luciferase reporter assays, siRNA knockdown of ARID3A, proliferation/differentiation/apoptosis assays","journal":"Leukemia","confidence":"High","confidence_rationale":"Tier 2 — luciferase reporter validates direct targeting; multiple orthogonal functional assays; replicated across murine and human cells","pmids":["22469780"],"is_preprint":false},{"year":2014,"finding":"Upregulation and nuclear entry of Arid3a drives trophectoderm (TE)-like transcriptional programs in ES cells, maintains trophoblast stem cell self-renewal, and promotes trophoblastic differentiation upstream and independent of Cdx2. Arid3a directly activates TE-specific genes while repressing pluripotency genes via differential regulation of histone acetylation/deacetylation. Arid3a-/- mice show severely impaired post-implantation placental development.","method":"Arid3a knockout mouse, ES cell overexpression/knockdown, ChIP for Arid3a at target promoters, histone acetylation assays, transcriptomic analysis, trophoblast stem cell self-renewal assays","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 1–2 — in vivo knockout plus ChIP plus epigenetic mechanism plus multiple cell-type functional assays; strong mechanistic evidence from single study","pmids":["25319825"],"is_preprint":false},{"year":2014,"finding":"ARID3a/Bright is expressed in hematopoietic stem/progenitor cells and regulates hematopoietic lineage decisions. In mice, over-expression skewed mature B cell subsets and altered follicular B cell gene expression, while loss of function eliminated B1 lineage B cells and caused hematopoietic defects. The protein interacts with DNA as a dimer through its ARID domain and requires association with other proteins to increase transcription of immunoglobulin heavy chain and chromatin accessibility at the heavy chain enhancer.","method":"Transgenic and knockout mouse models, gene expression profiling, B cell subset analysis by flow cytometry, DNA binding assays","journal":"Frontiers in immunology","confidence":"Medium","confidence_rationale":"Tier 2 — review synthesizing multiple prior experimental studies from same lab with mouse genetic models","pmids":["24678314"],"is_preprint":false},{"year":2015,"finding":"ARID3a is a key target of the miRNA Let-7 (regulated by Lin28b) in fetal B-cell progenitors. Ectopic ARID3a expression in adult pro-B cells is sufficient to induce B-1 development, while ARID3a knockdown blocks B-1 development in fetal pro-B cells, placing ARID3a downstream of Lin28b/Let-7 as a critical regulator of the fetal B-1 versus adult B-2 lymphopoiesis switch. Intact BCR signaling is also required for Lin28b-induced B1a cell generation.","method":"Retroviral transduction of Lin28b or ARID3a in adult bone marrow progenitors, Let-7 modulation, ARID3a knockdown in fetal pro-B cells, transplantation into immunodeficient recipients, VH repertoire analysis","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 — gain- and loss-of-function in defined progenitor populations with specific B cell lineage phenotypic readouts; strong mechanistic epistasis","pmids":["25753579"],"is_preprint":false},{"year":2015,"finding":"ARID3a is important for human hematopoiesis: inhibition of ARID3a in cord blood hematopoietic stem/progenitor cells decreased B lineage cell production and increased cells with myeloid markers, while ARID3a overexpression inhibited both myeloid and erythroid differentiation. ARID3a knockdown also altered expression of lineage-determining transcription factors.","method":"Lentiviral siRNA knockdown and overexpression of ARID3a in cord blood CD34+ HSCs, in vitro differentiation assays, flow cytometry for lineage markers, transcription factor expression analysis","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 — bidirectional genetic manipulation (KD and OE) in primary human HSCs with defined lineage phenotype","pmids":["26685208"],"is_preprint":false},{"year":2016,"finding":"ARID3a+ human B lymphocytes produce interferon alpha (IFNa). TLR9 agonist (CpG) stimulation induced both ARID3a expression and IFNa production in healthy control B cells. IFNa secreted from ARID3a+ B cells stimulated increased IFNa production in plasmacytoid dendritic cells, identifying ARID3a+ B cells as a novel effector B cell type linking ARID3a to IFN-associated inflammatory responses in SLE.","method":"Flow cytometry for ARID3a+ B cell sorting, CpG stimulation, ELISA for IFNa, co-culture with plasmacytoid dendritic cells, gene expression profiling for IFN signature genes","journal":"Journal of autoimmunity","confidence":"Medium","confidence_rationale":"Tier 2 — functional stimulation assays with primary human cells plus downstream cytokine cascade; moderate single-lab evidence","pmids":["27522115"],"is_preprint":false},{"year":2008,"finding":"ARID3A (Dril1) was identified as a novel binding partner for Id1 by protein interaction screening. Dril1 enhanced activation of TGF-β1 target genes in fibroblasts, while Id1 decreased their expression. Id1 inhibited DNA binding by Dril1, and the two proteins co-localized in vitro and in vivo, providing a mechanism by which Id1 suppresses fibrosis through inhibition of profibrotic Dril1 activity.","method":"Protein interaction screening, co-immunoprecipitation, co-localization (in vitro and in vivo), DNA binding assays, TGF-β1 target gene activation assays, Id1 knockout mouse bleomycin model","journal":"The American journal of pathology","confidence":"Medium","confidence_rationale":"Tier 2–3 — pulldown/Co-IP plus functional gene expression assays plus in vivo co-localization from single lab","pmids":["18583319"],"is_preprint":false},{"year":2005,"finding":"The Xenopus ortholog of ARID3A (Dril1) is required for TGF-β signaling during mesoderm induction. Morpholino depletion of dril1 inhibited gastrulation, blocked induction of mesodermal markers (Xbra, chordin, noggin, Xlim1), and prevented both smad2-mediated dorsal/endodermal induction and smad1-mediated ventral mesoderm induction in animal caps, while FGF-mediated mesoderm induction was unaffected, indicating pathway-specific regulation of TGF-β signaling.","method":"Morpholino knockdown, engrailed repressor-dril1 fusion constructs, animal cap assays, secondary axis induction assays, mRNA rescue experiments in Xenopus tropicalis","journal":"Developmental biology","confidence":"High","confidence_rationale":"Tier 2 — multiple loss-of-function approaches with pathway-specific epistasis in Xenopus embryos; rescue validates specificity","pmids":["15680369"],"is_preprint":false},{"year":2022,"finding":"ARID3A promotes megakaryocytic differentiation in concert with GATA1 and mediates TGF-β-induced apoptosis and cell cycle arrest in complex with SMAD2/3. miR-125b (encoded on chromosome 21) post-transcriptionally represses ARID3A, synergizing with GATA1s mutations to block megakaryocytic/erythroid differentiation and drive acute megakaryoblastic leukemia (AMKL). Restoring ARID3A expression in AMKL patient-derived xenografts relieved the differentiation block.","method":"Forward and reverse genetics, miR-125b overexpression/knockdown, ARID3A knockdown/restoration, Co-IP for SMAD2/3 complex, patient-derived xenograft model, flow cytometry for differentiation markers","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — multiple genetic approaches in primary cells and PDX models; Co-IP identifies SMAD2/3 complex; rescue experiment validates causal role","pmids":["34570885"],"is_preprint":false},{"year":2022,"finding":"ARID3A interacts with CEP131 and together they transcriptionally activate KDM3A by co-occupying its promoter, which in turn upregulates embryonic stem cell signature genes via demethylation of H3K9me2, promoting liver cancer stemness and metastasis.","method":"Co-immunoprecipitation of ARID3A-CEP131 complex, CUT&Tag chromatin profiling, RNA-seq, ChIP for H3K9me2, in vitro and in vivo functional assays (viability, metastasis)","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 — CUT&Tag plus Co-IP plus H3K9me2 ChIP from single lab with functional validation in vivo","pmids":["36008383"],"is_preprint":false},{"year":2023,"finding":"Arid3a negatively regulates Mertk transcription by directly binding to the Mertk promoter (demonstrated by ChIP-seq and luciferase reporter assay) in macrophages. Myeloid-specific Arid3a knockout enhanced Mertk-mediated efferocytosis of apoptotic cholangiocytes, alleviating cholestatic liver injury. In vivo Mertk inhibition reversed the protective phenotype of Arid3a deficiency.","method":"Myeloid-specific Arid3a knockout mouse, ChIP-seq, luciferase reporter assay, efferocytosis assays, in vivo Mertk inhibitor (UNC2025), flow cytometry, RNA-seq","journal":"Journal of hepatology","confidence":"High","confidence_rationale":"Tier 2 — ChIP-seq plus reporter assay plus in vivo rescue with Mertk inhibitor; strong mechanistic chain from ARID3A to Mertk to efferocytosis","pmids":["37659731"],"is_preprint":false},{"year":2024,"finding":"ARID3A transcriptionally represses PTEN expression (demonstrated by CUT&Tag profiling), leading to GPX4 upregulation and resistance to ferroptosis. ARID3A knockdown in pancreatic cancer cells alleviates PTEN transcriptional inhibition, resulting in GPX4 depletion, increased lipid peroxidation, and activated ferroptosis, thereby reducing gemcitabine chemoresistance in vitro and in vivo.","method":"CUT&Tag chromatin profiling, RNA-seq, ARID3A knockdown (siRNA/shRNA), overexpression, lipid peroxidation assays, GPX4 and PTEN Western blotting, in vivo tumor models, gemcitabine sensitivity assays","journal":"Redox biology","confidence":"Medium","confidence_rationale":"Tier 2 — CUT&Tag identifies direct PTEN promoter occupancy; functional ferroptosis and chemoresistance assays in vitro and in vivo from single lab","pmids":["38781729"],"is_preprint":false},{"year":2019,"finding":"miR-574-5p directly targets ARID3A (validated by luciferase reporter assay), and decreased ARID3A levels promote fibroblast-to-myofibroblast differentiation of human cardiac fibroblasts (HCFs) in TGF-β-induced conditions. Silencing miR-574-5p increased ARID3A and suppressed myofibroblast differentiation markers.","method":"Luciferase 3'UTR reporter assay, miR-574-5p overexpression/silencing in HCFs, ARID3A knockdown, fibrosis gene expression assays, wound healing and transwell migration assays","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 3 — luciferase reporter validates direct targeting; functional cardiac fibroblast differentiation assays; single lab","pmids":["31672272"],"is_preprint":false},{"year":2022,"finding":"ARID3A expression in macrophages is regulated by NEAT1 acting as a ceRNA to sponge miR-147a, preventing degradation of ARID3A mRNA. ARID3A binds to the promoter region of the let-7a/let-7f/let-7d gene cluster (confirmed by EMSA and ChIP) and inhibits let-7 family expression; NF-κB signaling inhibits let-7 expression by affecting nuclear import of ARID3A. The NEAT1/ARID3A/let-7 axis regulates macrophage polarization and PRRSV replication.","method":"EMSA, ChIP, luciferase reporter assay, RNA immunoprecipitation, miRNA sequencing, in vitro and in vivo PRRSV infection models","journal":"PLoS pathogens","confidence":"Medium","confidence_rationale":"Tier 2–3 — EMSA and ChIP validate direct promoter binding; multiple mechanistic nodes confirmed; single lab porcine model","pmids":["36215225"],"is_preprint":false},{"year":2001,"finding":"Bright/ARID3a increases immunoglobulin heavy chain transcription three- to sevenfold in antigen-activated B cells. It interacts with DNA through the ARID (A/T-rich interaction domain) and associates with nuclear matrix proteins sp100 and LYSp100B, suggesting it may affect chromatin configuration and nuclear sublocalization. Bruton's tyrosine kinase (Btk) is required for Bright DNA binding activity.","method":"Transcription reporter assays, ARID domain DNA-binding assays, co-immunoprecipitation with sp100/LYSp100B, Btk requirement for DNA binding activity","journal":"Immunologic research","confidence":"Medium","confidence_rationale":"Tier 3 — review of original experimental data; multiple protein interactions reported but individual experiments not detailed; moderate confidence from multiple observations","pmids":["11594453"],"is_preprint":false},{"year":2023,"finding":"A non-coding intronic variant in ARID3A (rs2238574) acts as an allele-specific enhancer in myeloid cells to regulate ARID3A expression. Luciferase reporter assay and allele-specific ChIP prioritized rs2238574 as causal; genome editing confirmed its regulatory effect. ARID3A knockdown inhibited myeloid differentiation and activation pathways, while overexpression had the opposite effect, functionally linking ARID3A levels to myeloid cell behavior.","method":"Luciferase reporter assay, allele-specific ChIP, CRISPR genome editing, ARID3A knockdown/overexpression in myeloid cells, myeloid differentiation assays","journal":"Nature communications","confidence":"Medium","confidence_rationale":"Tier 2 — luciferase plus allele-specific ChIP plus genome editing plus functional KD/OE; single lab but orthogonal methods","pmids":["36977669"],"is_preprint":false}],"current_model":"ARID3A (Bright) is an ARID-domain transcription factor that binds AT-rich DNA motifs as a dimer to activate immunoglobulin heavy-chain transcription via a three-component complex with TFII-I and Btk, promotes trophectoderm and placental development by activating TE-specific genes while repressing pluripotency genes through epigenetic acetylation changes, regulates hematopoietic lineage decisions (B-1 vs. B-2, megakaryocytic differentiation with GATA1/SMAD2/3), suppresses Mertk transcription by direct promoter binding in macrophages to impair efferocytosis, represses PTEN to inhibit ferroptosis in cancer cells, acts downstream of Lin28b/Let-7 to control fetal B lymphopoiesis, and modulates IFN-alpha production in B cells; its activity is post-transcriptionally controlled by miR-125b and miR-574-5p, and nuclear import is regulated by NF-κB signaling."},"narrative":{"teleology":[{"year":2001,"claim":"Establishing that ARID3A/Bright is a sequence-specific transcription factor that activates immunoglobulin heavy-chain transcription in B cells, binds AT-rich DNA via the ARID domain, associates with nuclear matrix proteins, and requires Btk for DNA binding activity answered the foundational question of how IgH locus accessibility is regulated.","evidence":"Transcription reporter assays, DNA binding assays, Co-IP with sp100/LYSp100B, Btk dependence in B cells","pmids":["11594453"],"confidence":"Medium","gaps":["Single-lab review of earlier data; individual experiments not independently detailed","Structural basis of ARID domain–DNA interaction unresolved","Mechanism by which Btk enables DNA binding not defined"]},{"year":2005,"claim":"Demonstrating that the Xenopus ARID3A ortholog is specifically required for TGF-β but not FGF-mediated mesoderm induction established ARID3A as a pathway-selective mediator of TGF-β/SMAD signaling during embryonic development.","evidence":"Morpholino knockdown, engrailed-Dril1 fusions, animal cap assays, and mRNA rescue in Xenopus tropicalis","pmids":["15680369"],"confidence":"High","gaps":["Mammalian relevance of TGF-β selectivity not directly tested","Biochemical mechanism linking ARID3A to SMAD complexes not defined in this system"]},{"year":2006,"claim":"Identifying a three-component Bright/TFII-I/Btk complex and showing that Btk-dependent TFII-I phosphorylation is essential for Bright-driven IgH transcription resolved how ARID3A integrates signaling input with transcriptional activation at the IgH locus.","evidence":"Co-immunoprecipitation, domain mapping, IgH reporter assays, and siRNA knockdown in B-cell lines","pmids":["16738337"],"confidence":"High","gaps":["Whether the ternary complex operates at endogenous chromatin genome-wide was untested","Stoichiometry and structural details of the complex unknown"]},{"year":2008,"claim":"Discovery that Id1 directly binds ARID3A/Dril1 and inhibits its DNA binding revealed a mechanism by which Id proteins suppress profibrotic gene activation downstream of TGF-β1.","evidence":"Protein interaction screen, Co-IP, co-localization, DNA binding assays, TGF-β1 target gene assays, Id1 KO mouse bleomycin model","pmids":["18583319"],"confidence":"Medium","gaps":["Single-lab finding; reciprocal validation limited","Whether Id1 inhibition of ARID3A generalizes beyond fibrosis context unknown"]},{"year":2010,"claim":"Showing that ARID3A loss in somatic cells induced pluripotency gene expression and multilineage differentiation capacity fundamentally reframed ARID3A from an immunoglobulin-specific factor to a broad repressor of developmental plasticity.","evidence":"Knockout mouse models, siRNA knockdown, colony formation, multi-lineage differentiation, gene expression profiling","pmids":["20680960"],"confidence":"High","gaps":["Epigenetic mechanism of pluripotency repression was not defined","Whether ARID3A loss achieves bona fide iPSC-equivalent reprogramming was unclear"]},{"year":2011,"claim":"Two discoveries in 2011 expanded ARID3A's mechanistic repertoire: cooperation with p53 to activate p21WAF1 at AT-rich promoter elements after DNA damage, and identification of ARID3C as a co-activating partner at IgH loci, revealed context-dependent transcriptional partnerships.","evidence":"ChIP, in vitro binding, reporter assays, siRNA in p53-positive/null lines (p21 study); Co-IP, DNA binding, IgH reporters, SUMO assays (ARID3C study)","pmids":["22172947","21955986"],"confidence":"High","gaps":["Genome-wide overlap of ARID3A and p53 co-regulation sites not mapped","ARID3C contribution relative to ARID3A at endogenous loci untested"]},{"year":2012,"claim":"Demonstrating that miR-125b directly targets ARID3A to block B-cell progenitor differentiation while conferring survival advantage established a post-transcriptional regulatory axis controlling ARID3A levels in hematopoiesis.","evidence":"3′UTR luciferase reporter, miR-125b overexpression/inhibition, ARID3A siRNA, proliferation and apoptosis assays in murine and human leukemic B-cell lines","pmids":["22469780"],"confidence":"High","gaps":["In vivo physiological relevance of miR-125b–ARID3A axis in normal B-cell development not directly shown here"]},{"year":2014,"claim":"Two parallel 2014 studies established ARID3A as a master regulator of early embryonic and hematopoietic lineage decisions: it drives trophectoderm specification upstream of Cdx2 via differential histone acetylation, and controls B-1 versus B-2 lineage allocation and chromatin accessibility at IgH enhancers.","evidence":"ARID3A KO mouse with placental defects, ES cell OE/KD, ChIP, histone acetylation assays (TE study); transgenic/KO mice, B cell subset flow cytometry, DNA binding assays (hematopoiesis study)","pmids":["25319825","24678314"],"confidence":"High","gaps":["Direct ARID3A target genes in trophoblast beyond a few markers not comprehensively defined","Mechanism by which ARID3A opens chromatin at IgH enhancer molecularly unclear"]},{"year":2015,"claim":"Placing ARID3A downstream of the Lin28b/Let-7 axis and showing its sufficiency to reprogram adult pro-B cells toward B-1 fate resolved a key step in the fetal-to-adult B lymphopoiesis switch and explained how a single transcription factor coordinates developmental timing with lineage output.","evidence":"Retroviral transduction of ARID3A/Lin28b in adult BM progenitors, Let-7 modulation, ARID3A KD in fetal pro-B cells, transplantation, VH repertoire analysis","pmids":["25753579"],"confidence":"High","gaps":["Direct transcriptional targets of ARID3A that enforce B-1 identity not identified","Whether ARID3A acts through chromatin remodeling or direct gene activation in this context unknown"]},{"year":2015,"claim":"Demonstrating that ARID3A knockdown in human cord blood HSCs shifted lineage output from B-lymphoid toward myeloid confirmed ARID3A as a conserved regulator of human multilineage hematopoietic decisions.","evidence":"Lentiviral KD and OE of ARID3A in cord blood CD34+ HSCs, in vitro differentiation, flow cytometry, transcription factor expression analysis","pmids":["26685208"],"confidence":"Medium","gaps":["In vitro system only; in vivo human HSC repopulation not tested","Downstream transcriptional programs mediating lineage bias not comprehensively mapped"]},{"year":2016,"claim":"Identifying ARID3A+ B cells as IFN-α producers following TLR9 stimulation linked ARID3A to innate immune effector function and inflammatory amplification relevant to SLE pathogenesis.","evidence":"ARID3a+ B cell sorting, CpG stimulation, IFN-α ELISA, co-culture with plasmacytoid dendritic cells","pmids":["27522115"],"confidence":"Medium","gaps":["Whether ARID3A directly regulates IFN-α gene transcription or acts indirectly is unknown","Causal role of ARID3A in SLE not established by genetic evidence"]},{"year":2019,"claim":"Validation that miR-574-5p directly targets ARID3A and modulates cardiac fibroblast-to-myofibroblast differentiation revealed a second miRNA axis regulating ARID3A levels in a non-hematopoietic, TGF-β-driven fibrotic context.","evidence":"3′UTR luciferase reporter, miR-574-5p OE/silencing, ARID3A KD in human cardiac fibroblasts","pmids":["31672272"],"confidence":"Medium","gaps":["Single-lab study; limited to in vitro cardiac fibroblast system","Whether ARID3A promotes or opposes fibrotic gene programs in this context appears opposite to the Id1 study — contradiction unresolved"]},{"year":2022,"claim":"Three 2022 studies expanded ARID3A's mechanism: (1) miR-125b repression of ARID3A cooperates with GATA1s to block megakaryocytic differentiation and drive AMKL, with ARID3A forming a complex with SMAD2/3; (2) ARID3A partners with CEP131 to activate KDM3A transcription, promoting cancer stemness via H3K9me2 demethylation; (3) ARID3A directly binds the let-7 gene cluster promoter to repress let-7 in macrophages, regulated by NF-κB-controlled nuclear import.","evidence":"Forward/reverse genetics and PDX rescue (AMKL); Co-IP, CUT&Tag, H3K9me2 ChIP (liver cancer); EMSA, ChIP, RIP, PRRSV infection models (macrophage/let-7)","pmids":["34570885","36008383","36215225"],"confidence":"High","gaps":["SMAD2/3–ARID3A complex composition and DNA targets not genome-wide mapped","CEP131–ARID3A interaction awaits independent replication","NF-κB–ARID3A nuclear import mechanism molecularly undefined"]},{"year":2023,"claim":"Two 2023 findings revealed ARID3A as a direct transcriptional repressor of Mertk in macrophages limiting efferocytosis, and identified a non-coding enhancer variant (rs2238574) that modulates ARID3A expression to control myeloid differentiation, connecting genetic regulation of ARID3A levels to myeloid functional output.","evidence":"Myeloid-specific KO mouse, ChIP-seq, reporter assays, Mertk inhibitor rescue in vivo (Mertk study); CRISPR editing, allele-specific ChIP, luciferase, KD/OE in myeloid cells (enhancer study)","pmids":["37659731","36977669"],"confidence":"High","gaps":["Additional direct ARID3A-repressed targets in macrophages beyond Mertk not mapped","rs2238574 functional impact on disease susceptibility in patient cohorts not established"]},{"year":2024,"claim":"Demonstrating that ARID3A directly represses PTEN transcription to sustain GPX4 and inhibit ferroptosis revealed a novel ARID3A–PTEN–ferroptosis axis mediating chemoresistance in pancreatic cancer.","evidence":"CUT&Tag, RNA-seq, ARID3A KD/OE, lipid peroxidation assays, GPX4/PTEN Western blots, in vivo tumor models, gemcitabine sensitivity assays","pmids":["38781729"],"confidence":"Medium","gaps":["Single-lab study; PTEN repression mechanism (cofactors, chromatin changes) not detailed","Generalizability beyond pancreatic cancer untested"]},{"year":null,"claim":"Major unresolved questions include the structural basis of ARID3A dimerization and DNA recognition, the genome-wide chromatin landscape it occupies across cell types, the molecular mechanism by which NF-κB controls its nuclear import, and how its activating versus repressive functions are contextually switched.","evidence":"","pmids":[],"confidence":"Low","gaps":["No crystal or cryo-EM structure of ARID3A or its complexes","No unified genome-wide binding map across hematopoietic, trophoblast, and cancer contexts","Molecular basis for context-dependent activation versus repression unresolved"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[0,2,5,6,10,14,17,18]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[0,2,5,13,14,15,17]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[2,5,17,18]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[0,2,5,13,14,15,17]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[7,8,9]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[5,7,11]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[11,12,17]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[4,12,15]}],"complexes":["Bright/TFII-I/Btk complex","ARID3A/SMAD2/3 complex","ARID3A/CEP131 complex"],"partners":["GTF2I","BTK","ARID3C","SMAD2","SMAD3","CEP131","ID1","TP53"],"other_free_text":[]},"mechanistic_narrative":"ARID3A is an ARID-domain transcription factor that binds AT-rich DNA motifs as a dimer to regulate cell fate decisions across multiple lineages, including B-lymphocyte differentiation, hematopoietic stem cell commitment, trophectoderm specification, and megakaryopoiesis. It activates immunoglobulin heavy-chain transcription through a ternary complex with TFII-I and Bruton's tyrosine kinase (Btk), where Btk-mediated phosphorylation of TFII-I is required for transcriptional activity [PMID:16738337, PMID:11594453], and it functions downstream of the Lin28b/Let-7 axis to specify fetal B-1 lymphopoiesis [PMID:25753579]. ARID3A acts as both a transcriptional activator and repressor depending on context: it directly activates trophectoderm genes while repressing pluripotency genes through differential histone acetylation [PMID:25319825], cooperates with p53 to activate p21WAF1 after DNA damage [PMID:22172947], represses Mertk transcription in macrophages to limit efferocytosis [PMID:37659731], and represses PTEN to inhibit ferroptosis in cancer cells [PMID:38781729]. Its expression is post-transcriptionally controlled by miR-125b and Let-7, and its nuclear import is regulated by NF-κB signaling; miR-125b-mediated repression of ARID3A synergizes with GATA1s mutations to drive acute megakaryoblastic leukemia [PMID:34570885, PMID:22469780, PMID:36215225]."},"prefetch_data":{"uniprot":{"accession":"Q99856","full_name":"AT-rich interactive domain-containing protein 3A","aliases":["B-cell regulator of IgH transcription","Bright","Dead ringer-like protein 1","E2F-binding protein 1"],"length_aa":593,"mass_kda":62.9,"function":"Transcription factor which may be involved in the control of cell cycle progression by the RB1/E2F1 pathway and in B-cell differentiation","subcellular_location":"Nucleus; Cytoplasm","url":"https://www.uniprot.org/uniprotkb/Q99856/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/ARID3A","classification":"Not Classified","n_dependent_lines":40,"n_total_lines":1208,"dependency_fraction":0.033112582781456956},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/ARID3A","total_profiled":1310},"omim":[{"mim_id":"620868","title":"AT-RICH INTERACTION DOMAIN-CONTAINING PROTEIN 3C; ARID3C","url":"https://www.omim.org/entry/620868"},{"mim_id":"612457","title":"AT-RICH INTERACTION DOMAIN-CONTAINING PROTEIN 3B; ARID3B","url":"https://www.omim.org/entry/612457"},{"mim_id":"611583","title":"AT-RICH INTERACTION DOMAIN-CONTAINING PROTEIN 5A; ARID5A","url":"https://www.omim.org/entry/611583"},{"mim_id":"603265","title":"AT-RICH INTERACTION DOMAIN-CONTAINING PROTEIN 3A; ARID3A","url":"https://www.omim.org/entry/603265"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"placenta","ntpm":22.0},{"tissue":"testis","ntpm":16.1}],"url":"https://www.proteinatlas.org/search/ARID3A"},"hgnc":{"alias_symbol":["BRIGHT"],"prev_symbol":["DRIL1"]},"alphafold":{"accession":"Q99856","domains":[{"cath_id":"1.10.150.60","chopping":"226-348","consensus_level":"high","plddt":95.0398,"start":226,"end":348}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q99856","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q99856-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q99856-F1-predicted_aligned_error_v6.png","plddt_mean":60.59},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ARID3A","jax_strain_url":"https://www.jax.org/strain/search?query=ARID3A"},"sequence":{"accession":"Q99856","fasta_url":"https://rest.uniprot.org/uniprotkb/Q99856.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q99856/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q99856"}},"corpus_meta":[{"pmid":"32060354","id":"PMC_32060354","title":"ROS in cancer therapy: the bright side of the moon.","date":"2020","source":"Experimental & molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32060354","citation_count":1485,"is_preprint":false},{"pmid":"7123238","id":"PMC_7123238","title":"Heritable true fitness and bright birds: a role for parasites?","date":"1982","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/7123238","citation_count":1370,"is_preprint":false},{"pmid":"23524392","id":"PMC_23524392","title":"A bright monomeric green fluorescent protein derived from Branchiostoma lanceolatum.","date":"2013","source":"Nature methods","url":"https://pubmed.ncbi.nlm.nih.gov/23524392","citation_count":1004,"is_preprint":false},{"pmid":"27869816","id":"PMC_27869816","title":"mScarlet: a bright monomeric red fluorescent protein for cellular imaging.","date":"2016","source":"Nature methods","url":"https://pubmed.ncbi.nlm.nih.gov/27869816","citation_count":852,"is_preprint":false},{"pmid":"17572680","id":"PMC_17572680","title":"Bright monomeric red fluorescent protein with an extended fluorescence lifetime.","date":"2007","source":"Nature methods","url":"https://pubmed.ncbi.nlm.nih.gov/17572680","citation_count":482,"is_preprint":false},{"pmid":"22581370","id":"PMC_22581370","title":"Rational design of true monomeric and bright photoactivatable fluorescent proteins.","date":"2012","source":"Nature methods","url":"https://pubmed.ncbi.nlm.nih.gov/22581370","citation_count":367,"is_preprint":false},{"pmid":"31371562","id":"PMC_31371562","title":"Bright and photostable chemigenetic indicators for extended in vivo voltage imaging.","date":"2019","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/31371562","citation_count":340,"is_preprint":false},{"pmid":"32979309","id":"PMC_32979309","title":"CAR T Cell Therapy for Solid Tumors: Bright Future or Dark Reality?","date":"2020","source":"Molecular therapy : the journal of the American Society of Gene Therapy","url":"https://pubmed.ncbi.nlm.nih.gov/32979309","citation_count":286,"is_preprint":false},{"pmid":"33189359","id":"PMC_33189359","title":"Extracellular vesicles: A bright star of nanomedicine.","date":"2020","source":"Biomaterials","url":"https://pubmed.ncbi.nlm.nih.gov/33189359","citation_count":271,"is_preprint":false},{"pmid":"31548726","id":"PMC_31548726","title":"Visualizing RNA dynamics in live cells with bright and stable fluorescent RNAs.","date":"2019","source":"Nature biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/31548726","citation_count":270,"is_preprint":false},{"pmid":"27539380","id":"PMC_27539380","title":"Bright monomeric near-infrared fluorescent proteins as tags and biosensors for multiscale imaging.","date":"2016","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/27539380","citation_count":231,"is_preprint":false},{"pmid":"10449183","id":"PMC_10449183","title":"Reporter gene technology: the future looks bright.","date":"1999","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/10449183","citation_count":223,"is_preprint":false},{"pmid":"35468954","id":"PMC_35468954","title":"A highly photostable and bright green fluorescent protein.","date":"2022","source":"Nature biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/35468954","citation_count":198,"is_preprint":false},{"pmid":"24114507","id":"PMC_24114507","title":"Immunosurveillance of senescent cells: the bright side of the senescence program.","date":"2013","source":"Biogerontology","url":"https://pubmed.ncbi.nlm.nih.gov/24114507","citation_count":174,"is_preprint":false},{"pmid":"25118186","id":"PMC_25118186","title":"Bright and fast multicoloured voltage reporters via electrochromic FRET.","date":"2014","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/25118186","citation_count":149,"is_preprint":false},{"pmid":"31845511","id":"PMC_31845511","title":"Electrochemical Sensors, a Bright Future in the Fabrication of Portable Kits in Analytical Systems.","date":"2019","source":"Chemical record (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/31845511","citation_count":141,"is_preprint":false},{"pmid":"32661427","id":"PMC_32661427","title":"Novel NanoLuc substrates enable bright two-population bioluminescence imaging in animals.","date":"2020","source":"Nature methods","url":"https://pubmed.ncbi.nlm.nih.gov/32661427","citation_count":139,"is_preprint":false},{"pmid":"30972335","id":"PMC_30972335","title":"NanoBRET: The Bright Future of Proximity-Based Assays.","date":"2019","source":"Frontiers in bioengineering and biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/30972335","citation_count":131,"is_preprint":false},{"pmid":"16084717","id":"PMC_16084717","title":"Anthocyans from fruits and vegetables--does bright colour signal cancer chemopreventive activity?","date":"2005","source":"European journal of cancer (Oxford, England : 1990)","url":"https://pubmed.ncbi.nlm.nih.gov/16084717","citation_count":124,"is_preprint":false},{"pmid":"34376677","id":"PMC_34376677","title":"The bright side of fibroblasts: molecular signature and regenerative cues in major organs.","date":"2021","source":"NPJ Regenerative medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34376677","citation_count":120,"is_preprint":false},{"pmid":"29298292","id":"PMC_29298292","title":"Imaging organoids: a bright future ahead.","date":"2018","source":"Nature methods","url":"https://pubmed.ncbi.nlm.nih.gov/29298292","citation_count":110,"is_preprint":false},{"pmid":"7513274","id":"PMC_7513274","title":"TOTO and YOYO: new very bright fluorochromes for DNA content analyses by flow cytometry.","date":"1994","source":"Cytometry","url":"https://pubmed.ncbi.nlm.nih.gov/7513274","citation_count":109,"is_preprint":false},{"pmid":"25753579","id":"PMC_25753579","title":"Lin28b promotes fetal B lymphopoiesis through the transcription factor Arid3a.","date":"2015","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25753579","citation_count":107,"is_preprint":false},{"pmid":"24814217","id":"PMC_24814217","title":"Pheomelanin-induced oxidative stress: bright and dark chemistry bridging red hair phenotype and melanoma.","date":"2014","source":"Pigment cell & melanoma research","url":"https://pubmed.ncbi.nlm.nih.gov/24814217","citation_count":106,"is_preprint":false},{"pmid":"21116486","id":"PMC_21116486","title":"DNA Encapsulation of Ten Silver Atoms Produces a Bright, Modulatable, Near Infrared-Emitting Cluster.","date":"2010","source":"The journal of physical chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/21116486","citation_count":103,"is_preprint":false},{"pmid":"27589732","id":"PMC_27589732","title":"PMEL Amyloid Fibril Formation: The Bright Steps of Pigmentation.","date":"2016","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/27589732","citation_count":93,"is_preprint":false},{"pmid":"25493636","id":"PMC_25493636","title":"18F-Labeled Peptides: The Future Is Bright.","date":"2014","source":"Molecules (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/25493636","citation_count":90,"is_preprint":false},{"pmid":"24383451","id":"PMC_24383451","title":"TIGAR, TIGAR, burning bright.","date":"2014","source":"Cancer & metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/24383451","citation_count":90,"is_preprint":false},{"pmid":"7979362","id":"PMC_7979362","title":"Thioredoxin: a multifunctional regulatory protein with a bright future in technology and medicine.","date":"1994","source":"Archives of biochemistry and biophysics","url":"https://pubmed.ncbi.nlm.nih.gov/7979362","citation_count":90,"is_preprint":false},{"pmid":"22991378","id":"PMC_22991378","title":"The bright and the dark sides of activin in wound healing and cancer.","date":"2012","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/22991378","citation_count":89,"is_preprint":false},{"pmid":"18600265","id":"PMC_18600265","title":"Bright molecules with sense, logic, numeracy and utility.","date":"2008","source":"Organic & biomolecular chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18600265","citation_count":87,"is_preprint":false},{"pmid":"17167795","id":"PMC_17167795","title":"Quantum dots and peptides: a bright future together.","date":"2007","source":"Biopolymers","url":"https://pubmed.ncbi.nlm.nih.gov/17167795","citation_count":80,"is_preprint":false},{"pmid":"28779979","id":"PMC_28779979","title":"Cancer secretome and inflammation: The bright and the dark sides of NF-κB.","date":"2017","source":"Seminars in cell & developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/28779979","citation_count":75,"is_preprint":false},{"pmid":"30529586","id":"PMC_30529586","title":"A bright future: optogenetics to dissect the spatiotemporal control of cell behavior.","date":"2018","source":"Current opinion in chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/30529586","citation_count":71,"is_preprint":false},{"pmid":"35179300","id":"PMC_35179300","title":"Exosomal lncRNA HMMR-AS1 mediates macrophage polarization through miR-147a/ARID3A axis under hypoxia and affects the progression of hepatocellular carcinoma.","date":"2022","source":"Environmental toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/35179300","citation_count":65,"is_preprint":false},{"pmid":"25512311","id":"PMC_25512311","title":"Bright fluorescent Streptococcus pneumoniae for live-cell imaging of host-pathogen interactions.","date":"2014","source":"Journal of bacteriology","url":"https://pubmed.ncbi.nlm.nih.gov/25512311","citation_count":61,"is_preprint":false},{"pmid":"38409224","id":"PMC_38409224","title":"Bright and stable monomeric green fluorescent protein derived from StayGold.","date":"2024","source":"Nature methods","url":"https://pubmed.ncbi.nlm.nih.gov/38409224","citation_count":60,"is_preprint":false},{"pmid":"11682170","id":"PMC_11682170","title":"Green fluorescent protein--a bright idea for the study of bacterial protein localization.","date":"2001","source":"FEMS microbiology letters","url":"https://pubmed.ncbi.nlm.nih.gov/11682170","citation_count":60,"is_preprint":false},{"pmid":"32958033","id":"PMC_32958033","title":"The bright and the dark sides of L-carnitine supplementation: a systematic review.","date":"2020","source":"Journal of the International Society of Sports Nutrition","url":"https://pubmed.ncbi.nlm.nih.gov/32958033","citation_count":57,"is_preprint":false},{"pmid":"33637723","id":"PMC_33637723","title":"Ultra-bright Raman dots for multiplexed optical imaging.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/33637723","citation_count":55,"is_preprint":false},{"pmid":"16738337","id":"PMC_16738337","title":"Induction of immunoglobulin heavy-chain transcription through the transcription factor Bright requires TFII-I.","date":"2006","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/16738337","citation_count":52,"is_preprint":false},{"pmid":"22469780","id":"PMC_22469780","title":"B-cell regulator of immunoglobulin heavy-chain transcription (Bright)/ARID3a is a direct target of the oncomir microRNA-125b in progenitor B-cells.","date":"2012","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/22469780","citation_count":50,"is_preprint":false},{"pmid":"31430138","id":"PMC_31430138","title":"Isomeric Tuning Yields Bright and Targetable Red Ca2+ Indicators.","date":"2019","source":"Journal of the American Chemical Society","url":"https://pubmed.ncbi.nlm.nih.gov/31430138","citation_count":48,"is_preprint":false},{"pmid":"32121243","id":"PMC_32121243","title":"Novel Genetically Encoded Bright Positive Calcium Indicator NCaMP7 Based on the mNeonGreen Fluorescent Protein.","date":"2020","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32121243","citation_count":47,"is_preprint":false},{"pmid":"26056741","id":"PMC_26056741","title":"Dark dyes-bright complexes: fluorogenic protein labeling.","date":"2015","source":"Current opinion in chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/26056741","citation_count":47,"is_preprint":false},{"pmid":"20680960","id":"PMC_20680960","title":"Loss of Bright/ARID3a function promotes developmental plasticity.","date":"2010","source":"Stem cells (Dayton, Ohio)","url":"https://pubmed.ncbi.nlm.nih.gov/20680960","citation_count":46,"is_preprint":false},{"pmid":"22237699","id":"PMC_22237699","title":"Dipolar 3-methoxychromones as bright and highly solvatochromic fluorescent dyes.","date":"2012","source":"Physical chemistry chemical physics : PCCP","url":"https://pubmed.ncbi.nlm.nih.gov/22237699","citation_count":45,"is_preprint":false},{"pmid":"35550530","id":"PMC_35550530","title":"CD39 - A bright target for cancer immunotherapy.","date":"2022","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/35550530","citation_count":43,"is_preprint":false},{"pmid":"25319825","id":"PMC_25319825","title":"Arid3a is essential to execution of the first cell fate decision via direct embryonic and extraembryonic transcriptional regulation.","date":"2014","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/25319825","citation_count":43,"is_preprint":false},{"pmid":"36455608","id":"PMC_36455608","title":"CAR T-cell therapies in China: rapid evolution and a bright future.","date":"2022","source":"The Lancet. Haematology","url":"https://pubmed.ncbi.nlm.nih.gov/36455608","citation_count":42,"is_preprint":false},{"pmid":"28638470","id":"PMC_28638470","title":"Bright Polymer Dots Tracking Stem Cell Engraftment and Migration to Injured Mouse Liver.","date":"2017","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/28638470","citation_count":42,"is_preprint":false},{"pmid":"32265667","id":"PMC_32265667","title":"A Bright and Colorful Future for G-Protein Coupled Receptor Sensors.","date":"2020","source":"Frontiers in cellular neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/32265667","citation_count":41,"is_preprint":false},{"pmid":"36658339","id":"PMC_36658339","title":"Avidity-based bright and photostable light-up aptamers for single-molecule mRNA imaging.","date":"2023","source":"Nature chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/36658339","citation_count":38,"is_preprint":false},{"pmid":"30637228","id":"PMC_30637228","title":"Sulfonylurea and neuroprotection: The bright side of the moon.","date":"2018","source":"Journal of advanced pharmaceutical technology & research","url":"https://pubmed.ncbi.nlm.nih.gov/30637228","citation_count":38,"is_preprint":false},{"pmid":"36865927","id":"PMC_36865927","title":"Protein dynamics: The future is bright and complicated!","date":"2023","source":"Structural dynamics (Melville, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/36865927","citation_count":38,"is_preprint":false},{"pmid":"38783134","id":"PMC_38783134","title":"Imaging the dynamics of messenger RNA with a bright and stable green fluorescent RNA.","date":"2024","source":"Nature chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/38783134","citation_count":36,"is_preprint":false},{"pmid":"33777673","id":"PMC_33777673","title":"Can nanoparticles and nano‒protein interactions bring a bright future for insulin delivery?","date":"2020","source":"Acta pharmaceutica Sinica. B","url":"https://pubmed.ncbi.nlm.nih.gov/33777673","citation_count":35,"is_preprint":false},{"pmid":"21508113","id":"PMC_21508113","title":"In vivo confocal microscopy of conjunctival roundish bright objects: young, older, and Sjögren subjects.","date":"2011","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/21508113","citation_count":35,"is_preprint":false},{"pmid":"36761757","id":"PMC_36761757","title":"Bright future or blind alley? CAR-T cell therapy for solid tumors.","date":"2023","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/36761757","citation_count":34,"is_preprint":false},{"pmid":"29780479","id":"PMC_29780479","title":"Pentacyclic adenine: a versatile and exceptionally bright fluorescent DNA base analogue.","date":"2018","source":"Chemical science","url":"https://pubmed.ncbi.nlm.nih.gov/29780479","citation_count":33,"is_preprint":false},{"pmid":"37659731","id":"PMC_37659731","title":"A+T rich interaction domain protein 3a (Arid3a) impairs Mertk-mediated efferocytosis in cholestasis.","date":"2023","source":"Journal of hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/37659731","citation_count":31,"is_preprint":false},{"pmid":"34570885","id":"PMC_34570885","title":"The megakaryocytic transcription factor ARID3A suppresses leukemia pathogenesis.","date":"2022","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/34570885","citation_count":31,"is_preprint":false},{"pmid":"33022173","id":"PMC_33022173","title":"Stealth and Bright Monomolecular Fluorescent Organic Nanoparticles Based on Folded Amphiphilic Polymer.","date":"2020","source":"ACS nano","url":"https://pubmed.ncbi.nlm.nih.gov/33022173","citation_count":30,"is_preprint":false},{"pmid":"35709514","id":"PMC_35709514","title":"Directed Evolution of a Bright Variant of mCherry: Suppression of Nonradiative Decay by Fluorescence Lifetime Selections.","date":"2022","source":"The journal of physical chemistry. B","url":"https://pubmed.ncbi.nlm.nih.gov/35709514","citation_count":29,"is_preprint":false},{"pmid":"23597020","id":"PMC_23597020","title":"Bright ion channels and lipid bilayers.","date":"2013","source":"Accounts of chemical research","url":"https://pubmed.ncbi.nlm.nih.gov/23597020","citation_count":28,"is_preprint":false},{"pmid":"36215225","id":"PMC_36215225","title":"miRNA let-7 family regulated by NEAT1 and ARID3A/NF-κB inhibits PRRSV-2 replication in vitro and in vivo.","date":"2022","source":"PLoS pathogens","url":"https://pubmed.ncbi.nlm.nih.gov/36215225","citation_count":28,"is_preprint":false},{"pmid":"39325256","id":"PMC_39325256","title":"Personalized neoantigen cancer vaccines: current progression, challenges and a bright future.","date":"2024","source":"Clinical and experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/39325256","citation_count":28,"is_preprint":false},{"pmid":"20396397","id":"PMC_20396397","title":"The bright and the dark sides of DNA repair in stem cells.","date":"2010","source":"Journal of biomedicine & biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/20396397","citation_count":28,"is_preprint":false},{"pmid":"38350967","id":"PMC_38350967","title":"The role of CD56bright NK cells in neurodegenerative disorders.","date":"2024","source":"Journal of neuroinflammation","url":"https://pubmed.ncbi.nlm.nih.gov/38350967","citation_count":28,"is_preprint":false},{"pmid":"24678314","id":"PMC_24678314","title":"The Bright Side of Hematopoiesis: Regulatory Roles of ARID3a/Bright in Human and Mouse Hematopoiesis.","date":"2014","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/24678314","citation_count":28,"is_preprint":false},{"pmid":"31650642","id":"PMC_31650642","title":"Trophoblast-derived CXCL12 promotes CD56bright CD82- CD29+ NK cell enrichment in the decidua.","date":"2019","source":"American journal of reproductive immunology (New York, N.Y. : 1989)","url":"https://pubmed.ncbi.nlm.nih.gov/31650642","citation_count":27,"is_preprint":false},{"pmid":"38781729","id":"PMC_38781729","title":"ARID3A enhances chemoresistance of pancreatic cancer via inhibiting PTEN-induced ferroptosis.","date":"2024","source":"Redox biology","url":"https://pubmed.ncbi.nlm.nih.gov/38781729","citation_count":26,"is_preprint":false},{"pmid":"27522115","id":"PMC_27522115","title":"Human effector B lymphocytes express ARID3a and secrete interferon alpha.","date":"2016","source":"Journal of autoimmunity","url":"https://pubmed.ncbi.nlm.nih.gov/27522115","citation_count":26,"is_preprint":false},{"pmid":"31553605","id":"PMC_31553605","title":"Carotenoid Nuclear Reorganization and Interplay of Bright and Dark Excited States.","date":"2019","source":"The journal of physical chemistry. B","url":"https://pubmed.ncbi.nlm.nih.gov/31553605","citation_count":26,"is_preprint":false},{"pmid":"30900089","id":"PMC_30900089","title":"Vaccine vectors: the bright side of cytomegalovirus.","date":"2019","source":"Medical microbiology and immunology","url":"https://pubmed.ncbi.nlm.nih.gov/30900089","citation_count":24,"is_preprint":false},{"pmid":"30430932","id":"PMC_30430932","title":"Building on Success: A Bright Future for Peptide Therapeutics.","date":"2018","source":"Protein and peptide letters","url":"https://pubmed.ncbi.nlm.nih.gov/30430932","citation_count":24,"is_preprint":false},{"pmid":"34928570","id":"PMC_34928570","title":"Amplified Fluorescence in Situ Hybridization by Small and Bright Dye-Loaded Polymeric Nanoparticles.","date":"2021","source":"ACS nano","url":"https://pubmed.ncbi.nlm.nih.gov/34928570","citation_count":23,"is_preprint":false},{"pmid":"30686614","id":"PMC_30686614","title":"Haem Biology in Metazoan Parasites - 'The Bright Side of Haem'.","date":"2019","source":"Trends in parasitology","url":"https://pubmed.ncbi.nlm.nih.gov/30686614","citation_count":23,"is_preprint":false},{"pmid":"28690964","id":"PMC_28690964","title":"Bright fluorescent silica-nanoparticle probes for high-resolution STED and confocal microscopy.","date":"2017","source":"Beilstein journal of nanotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/28690964","citation_count":22,"is_preprint":false},{"pmid":"18583319","id":"PMC_18583319","title":"Cross talk between Id1 and its interactive protein Dril1 mediate fibroblast responses to transforming growth factor-beta in pulmonary fibrosis.","date":"2008","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/18583319","citation_count":22,"is_preprint":false},{"pmid":"26685208","id":"PMC_26685208","title":"The Transcription Factor ARID3a Is Important for In Vitro Differentiation of Human Hematopoietic Progenitors.","date":"2015","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/26685208","citation_count":22,"is_preprint":false},{"pmid":"27224746","id":"PMC_27224746","title":"The bright side of plasmonic gold nanoparticles; activation of Nrf2, the cellular protective pathway.","date":"2016","source":"Nanoscale","url":"https://pubmed.ncbi.nlm.nih.gov/27224746","citation_count":22,"is_preprint":false},{"pmid":"21955986","id":"PMC_21955986","title":"Characterization of a new ARID family transcription factor (Brightlike/ARID3C) that co-activates Bright/ARID3A-mediated immunoglobulin gene transcription.","date":"2011","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/21955986","citation_count":22,"is_preprint":false},{"pmid":"38505631","id":"PMC_38505631","title":"Extracting quantitative biological information from bright-field cell images using deep learning.","date":"2021","source":"Biophysics reviews","url":"https://pubmed.ncbi.nlm.nih.gov/38505631","citation_count":21,"is_preprint":false},{"pmid":"28815751","id":"PMC_28815751","title":"Flow cytometry in Spermatology: A bright future ahead.","date":"2017","source":"Reproduction in domestic animals = Zuchthygiene","url":"https://pubmed.ncbi.nlm.nih.gov/28815751","citation_count":20,"is_preprint":false},{"pmid":"31614870","id":"PMC_31614870","title":"The Bright and Dark Side of DNA Methylation: A Matter of Balance.","date":"2019","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/31614870","citation_count":20,"is_preprint":false},{"pmid":"36008383","id":"PMC_36008383","title":"Hepatic ARID3A facilitates liver cancer malignancy by cooperating with CEP131 to regulate an embryonic stem cell-like gene signature.","date":"2022","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/36008383","citation_count":20,"is_preprint":false},{"pmid":"29148503","id":"PMC_29148503","title":"Highly surface functionalized carbon nano-onions for bright light bioimaging.","date":"2015","source":"Methods and applications in fluorescence","url":"https://pubmed.ncbi.nlm.nih.gov/29148503","citation_count":20,"is_preprint":false},{"pmid":"31672272","id":"PMC_31672272","title":"MiR-574-5p promotes the differentiation of human cardiac fibroblasts via regulating ARID3A.","date":"2019","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/31672272","citation_count":20,"is_preprint":false},{"pmid":"36674884","id":"PMC_36674884","title":"Spotlight on P2X7 Receptor PET Imaging: A Bright Target or a Failing Star?","date":"2023","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36674884","citation_count":19,"is_preprint":false},{"pmid":"22172947","id":"PMC_22172947","title":"Cooperation between ARID3A and p53 in the transcriptional activation of p21WAF1 in response to DNA damage.","date":"2011","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/22172947","citation_count":19,"is_preprint":false},{"pmid":"15680369","id":"PMC_15680369","title":"The ARID domain protein dril1 is necessary for TGF(beta) signaling in Xenopus embryos.","date":"2005","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/15680369","citation_count":17,"is_preprint":false},{"pmid":"35133831","id":"PMC_35133831","title":"Engineering Bright and Mechanosensitive Alkaline-Earth Rare-Earth Upconverting Nanoparticles.","date":"2022","source":"The journal of physical chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/35133831","citation_count":16,"is_preprint":false},{"pmid":"36929909","id":"PMC_36929909","title":"Diversified Mammalian Visuasl Adaptations to Bright- or Dim-Light Environments.","date":"2023","source":"Molecular biology and evolution","url":"https://pubmed.ncbi.nlm.nih.gov/36929909","citation_count":16,"is_preprint":false},{"pmid":"33494691","id":"PMC_33494691","title":"Novel Strategy in Breast Cancer Therapy: Revealing The Bright Side of Ginsenosides.","date":"2021","source":"Current molecular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/33494691","citation_count":16,"is_preprint":false},{"pmid":"11594453","id":"PMC_11594453","title":"The transcription factor, Bright, and immunoglobulin heavy chain expression.","date":"2001","source":"Immunologic research","url":"https://pubmed.ncbi.nlm.nih.gov/11594453","citation_count":15,"is_preprint":false},{"pmid":"38605649","id":"PMC_38605649","title":"2X-Rhodamine: A Bright and Fluorogenic Scaffold for Developing Near-Infrared Chemigenetic Indicators.","date":"2024","source":"Journal of the American Chemical Society","url":"https://pubmed.ncbi.nlm.nih.gov/38605649","citation_count":15,"is_preprint":false},{"pmid":"7252254","id":"PMC_7252254","title":"Photobiology and photomedicine: the future is bright.","date":"1981","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/7252254","citation_count":15,"is_preprint":false},{"pmid":"31554207","id":"PMC_31554207","title":"New Frontiers: ARID3a in SLE.","date":"2019","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/31554207","citation_count":14,"is_preprint":false},{"pmid":"36977669","id":"PMC_36977669","title":"A regulatory variant at 19p13.3 is associated with primary biliary cholangitis risk and ARID3A expression.","date":"2023","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/36977669","citation_count":14,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":39788,"output_tokens":5780,"usd":0.103032},"stage2":{"model":"claude-opus-4-6","input_tokens":9304,"output_tokens":4341,"usd":0.232568},"total_usd":0.3356,"stage1_batch_id":"msgbatch_01TqNM6p6FsoMBT2jzQTwKBr","stage2_batch_id":"msgbatch_01Ya473eco8sTHbvRymQaU8o","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2006,\n      \"finding\": \"ARID3A (Bright) directly interacts with TFII-I through amino acids in Bright's protein interaction domain, and specific tyrosine residues of TFII-I (phosphorylated by Bruton's tyrosine kinase, Btk) are essential for Bright-induced immunoglobulin heavy-chain reporter gene activity. Inhibition of TFII-I in B cells decreased heavy-chain transcript levels, identifying a three-component complex (Bright/TFII-I/Btk) required for immunoglobulin transcription.\",\n      \"method\": \"Co-immunoprecipitation, domain-mapping interaction assays, immunoglobulin reporter gene assays, siRNA inhibition of TFII-I in B-cell lines\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal interaction mapping plus functional reporter assay and knockdown, moderate evidence from single lab with multiple orthogonal methods\",\n      \"pmids\": [\"16738337\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Loss of Bright/ARID3a function (via knockout mouse models or direct siRNA knockdown of human Bright) promotes developmental plasticity: Bright-deficient somatic cells expressed pluripotency-associated gene products, expanded indefinitely, and spontaneously differentiated into cells of multiple lineages, indicating Bright normally represses pluripotency.\",\n      \"method\": \"Knockout mouse models, siRNA knockdown, colony formation assays, multi-lineage differentiation assays, gene expression profiling\",\n      \"journal\": \"Stem cells (Dayton, Ohio)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — three independent lines of evidence including two mouse models and human cell knockdown with defined pluripotency phenotype\",\n      \"pmids\": [\"20680960\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"ARID3A cooperates with p53 to transcriptionally activate p21WAF1 in response to DNA damage. ARID3A binds directly to AT-rich sites in the p21WAF1 promoter in vitro and in vivo (ChIP), and its knockdown suppressed p21WAF1 transcription after DNA damage without affecting NOXA or PUMA. Additionally, p53 and ARID3A show interdependence: p53 knockdown decreased ARID3A transcription, and ARID3A overexpression/knockdown increased/decreased p53 stability.\",\n      \"method\": \"ChIP, in vitro DNA binding, reporter gene assays, siRNA knockdown, co-expression studies in p53-positive and p53-null cell lines\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (ChIP, in vitro binding, functional reporter, KD with specific phenotype) in a single study\",\n      \"pmids\": [\"22172947\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"A third ARID3 family member, Brightlike/ARID3C, physically associates with ARID3A (Bright) in solution and at common DNA binding sites in vitro, and co-activates Bright-dependent IgH transcription. Brightlike undergoes nuclear-cytoplasmic shuttling dependent on the REKLES domain and localizes to lipid rafts after BCR stimulation. Sumoylation of Brightlike reduces its co-activation capacity.\",\n      \"method\": \"Co-immunoprecipitation, in vitro DNA binding, IgH reporter gene assays, nuclear-cytoplasmic fractionation, lipid raft fractionation, SUMO modification assays\",\n      \"journal\": \"Molecular immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2/3 — multiple methods from a single lab with functional reporter validation\",\n      \"pmids\": [\"21955986\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"miR-125b directly targets and represses ARID3A/Bright in B-cell progenitors, and this repression blocks differentiation while conferring a survival advantage. Forced Bright/ARID3A repression in pre-BI cells mimicked miR-125b-induced differentiation blockade, increased proliferation, and inhibited apoptosis via caspase pathway inhibition independent of p53 and BAK1.\",\n      \"method\": \"miR-125b overexpression/inhibition in murine and human leukemic B-cell lines, 3'UTR luciferase reporter assays, siRNA knockdown of ARID3A, proliferation/differentiation/apoptosis assays\",\n      \"journal\": \"Leukemia\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — luciferase reporter validates direct targeting; multiple orthogonal functional assays; replicated across murine and human cells\",\n      \"pmids\": [\"22469780\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Upregulation and nuclear entry of Arid3a drives trophectoderm (TE)-like transcriptional programs in ES cells, maintains trophoblast stem cell self-renewal, and promotes trophoblastic differentiation upstream and independent of Cdx2. Arid3a directly activates TE-specific genes while repressing pluripotency genes via differential regulation of histone acetylation/deacetylation. Arid3a-/- mice show severely impaired post-implantation placental development.\",\n      \"method\": \"Arid3a knockout mouse, ES cell overexpression/knockdown, ChIP for Arid3a at target promoters, histone acetylation assays, transcriptomic analysis, trophoblast stem cell self-renewal assays\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — in vivo knockout plus ChIP plus epigenetic mechanism plus multiple cell-type functional assays; strong mechanistic evidence from single study\",\n      \"pmids\": [\"25319825\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"ARID3a/Bright is expressed in hematopoietic stem/progenitor cells and regulates hematopoietic lineage decisions. In mice, over-expression skewed mature B cell subsets and altered follicular B cell gene expression, while loss of function eliminated B1 lineage B cells and caused hematopoietic defects. The protein interacts with DNA as a dimer through its ARID domain and requires association with other proteins to increase transcription of immunoglobulin heavy chain and chromatin accessibility at the heavy chain enhancer.\",\n      \"method\": \"Transgenic and knockout mouse models, gene expression profiling, B cell subset analysis by flow cytometry, DNA binding assays\",\n      \"journal\": \"Frontiers in immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — review synthesizing multiple prior experimental studies from same lab with mouse genetic models\",\n      \"pmids\": [\"24678314\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"ARID3a is a key target of the miRNA Let-7 (regulated by Lin28b) in fetal B-cell progenitors. Ectopic ARID3a expression in adult pro-B cells is sufficient to induce B-1 development, while ARID3a knockdown blocks B-1 development in fetal pro-B cells, placing ARID3a downstream of Lin28b/Let-7 as a critical regulator of the fetal B-1 versus adult B-2 lymphopoiesis switch. Intact BCR signaling is also required for Lin28b-induced B1a cell generation.\",\n      \"method\": \"Retroviral transduction of Lin28b or ARID3a in adult bone marrow progenitors, Let-7 modulation, ARID3a knockdown in fetal pro-B cells, transplantation into immunodeficient recipients, VH repertoire analysis\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — gain- and loss-of-function in defined progenitor populations with specific B cell lineage phenotypic readouts; strong mechanistic epistasis\",\n      \"pmids\": [\"25753579\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"ARID3a is important for human hematopoiesis: inhibition of ARID3a in cord blood hematopoietic stem/progenitor cells decreased B lineage cell production and increased cells with myeloid markers, while ARID3a overexpression inhibited both myeloid and erythroid differentiation. ARID3a knockdown also altered expression of lineage-determining transcription factors.\",\n      \"method\": \"Lentiviral siRNA knockdown and overexpression of ARID3a in cord blood CD34+ HSCs, in vitro differentiation assays, flow cytometry for lineage markers, transcription factor expression analysis\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — bidirectional genetic manipulation (KD and OE) in primary human HSCs with defined lineage phenotype\",\n      \"pmids\": [\"26685208\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"ARID3a+ human B lymphocytes produce interferon alpha (IFNa). TLR9 agonist (CpG) stimulation induced both ARID3a expression and IFNa production in healthy control B cells. IFNa secreted from ARID3a+ B cells stimulated increased IFNa production in plasmacytoid dendritic cells, identifying ARID3a+ B cells as a novel effector B cell type linking ARID3a to IFN-associated inflammatory responses in SLE.\",\n      \"method\": \"Flow cytometry for ARID3a+ B cell sorting, CpG stimulation, ELISA for IFNa, co-culture with plasmacytoid dendritic cells, gene expression profiling for IFN signature genes\",\n      \"journal\": \"Journal of autoimmunity\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional stimulation assays with primary human cells plus downstream cytokine cascade; moderate single-lab evidence\",\n      \"pmids\": [\"27522115\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"ARID3A (Dril1) was identified as a novel binding partner for Id1 by protein interaction screening. Dril1 enhanced activation of TGF-β1 target genes in fibroblasts, while Id1 decreased their expression. Id1 inhibited DNA binding by Dril1, and the two proteins co-localized in vitro and in vivo, providing a mechanism by which Id1 suppresses fibrosis through inhibition of profibrotic Dril1 activity.\",\n      \"method\": \"Protein interaction screening, co-immunoprecipitation, co-localization (in vitro and in vivo), DNA binding assays, TGF-β1 target gene activation assays, Id1 knockout mouse bleomycin model\",\n      \"journal\": \"The American journal of pathology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — pulldown/Co-IP plus functional gene expression assays plus in vivo co-localization from single lab\",\n      \"pmids\": [\"18583319\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"The Xenopus ortholog of ARID3A (Dril1) is required for TGF-β signaling during mesoderm induction. Morpholino depletion of dril1 inhibited gastrulation, blocked induction of mesodermal markers (Xbra, chordin, noggin, Xlim1), and prevented both smad2-mediated dorsal/endodermal induction and smad1-mediated ventral mesoderm induction in animal caps, while FGF-mediated mesoderm induction was unaffected, indicating pathway-specific regulation of TGF-β signaling.\",\n      \"method\": \"Morpholino knockdown, engrailed repressor-dril1 fusion constructs, animal cap assays, secondary axis induction assays, mRNA rescue experiments in Xenopus tropicalis\",\n      \"journal\": \"Developmental biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple loss-of-function approaches with pathway-specific epistasis in Xenopus embryos; rescue validates specificity\",\n      \"pmids\": [\"15680369\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"ARID3A promotes megakaryocytic differentiation in concert with GATA1 and mediates TGF-β-induced apoptosis and cell cycle arrest in complex with SMAD2/3. miR-125b (encoded on chromosome 21) post-transcriptionally represses ARID3A, synergizing with GATA1s mutations to block megakaryocytic/erythroid differentiation and drive acute megakaryoblastic leukemia (AMKL). Restoring ARID3A expression in AMKL patient-derived xenografts relieved the differentiation block.\",\n      \"method\": \"Forward and reverse genetics, miR-125b overexpression/knockdown, ARID3A knockdown/restoration, Co-IP for SMAD2/3 complex, patient-derived xenograft model, flow cytometry for differentiation markers\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple genetic approaches in primary cells and PDX models; Co-IP identifies SMAD2/3 complex; rescue experiment validates causal role\",\n      \"pmids\": [\"34570885\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"ARID3A interacts with CEP131 and together they transcriptionally activate KDM3A by co-occupying its promoter, which in turn upregulates embryonic stem cell signature genes via demethylation of H3K9me2, promoting liver cancer stemness and metastasis.\",\n      \"method\": \"Co-immunoprecipitation of ARID3A-CEP131 complex, CUT&Tag chromatin profiling, RNA-seq, ChIP for H3K9me2, in vitro and in vivo functional assays (viability, metastasis)\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — CUT&Tag plus Co-IP plus H3K9me2 ChIP from single lab with functional validation in vivo\",\n      \"pmids\": [\"36008383\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Arid3a negatively regulates Mertk transcription by directly binding to the Mertk promoter (demonstrated by ChIP-seq and luciferase reporter assay) in macrophages. Myeloid-specific Arid3a knockout enhanced Mertk-mediated efferocytosis of apoptotic cholangiocytes, alleviating cholestatic liver injury. In vivo Mertk inhibition reversed the protective phenotype of Arid3a deficiency.\",\n      \"method\": \"Myeloid-specific Arid3a knockout mouse, ChIP-seq, luciferase reporter assay, efferocytosis assays, in vivo Mertk inhibitor (UNC2025), flow cytometry, RNA-seq\",\n      \"journal\": \"Journal of hepatology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — ChIP-seq plus reporter assay plus in vivo rescue with Mertk inhibitor; strong mechanistic chain from ARID3A to Mertk to efferocytosis\",\n      \"pmids\": [\"37659731\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"ARID3A transcriptionally represses PTEN expression (demonstrated by CUT&Tag profiling), leading to GPX4 upregulation and resistance to ferroptosis. ARID3A knockdown in pancreatic cancer cells alleviates PTEN transcriptional inhibition, resulting in GPX4 depletion, increased lipid peroxidation, and activated ferroptosis, thereby reducing gemcitabine chemoresistance in vitro and in vivo.\",\n      \"method\": \"CUT&Tag chromatin profiling, RNA-seq, ARID3A knockdown (siRNA/shRNA), overexpression, lipid peroxidation assays, GPX4 and PTEN Western blotting, in vivo tumor models, gemcitabine sensitivity assays\",\n      \"journal\": \"Redox biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — CUT&Tag identifies direct PTEN promoter occupancy; functional ferroptosis and chemoresistance assays in vitro and in vivo from single lab\",\n      \"pmids\": [\"38781729\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"miR-574-5p directly targets ARID3A (validated by luciferase reporter assay), and decreased ARID3A levels promote fibroblast-to-myofibroblast differentiation of human cardiac fibroblasts (HCFs) in TGF-β-induced conditions. Silencing miR-574-5p increased ARID3A and suppressed myofibroblast differentiation markers.\",\n      \"method\": \"Luciferase 3'UTR reporter assay, miR-574-5p overexpression/silencing in HCFs, ARID3A knockdown, fibrosis gene expression assays, wound healing and transwell migration assays\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — luciferase reporter validates direct targeting; functional cardiac fibroblast differentiation assays; single lab\",\n      \"pmids\": [\"31672272\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"ARID3A expression in macrophages is regulated by NEAT1 acting as a ceRNA to sponge miR-147a, preventing degradation of ARID3A mRNA. ARID3A binds to the promoter region of the let-7a/let-7f/let-7d gene cluster (confirmed by EMSA and ChIP) and inhibits let-7 family expression; NF-κB signaling inhibits let-7 expression by affecting nuclear import of ARID3A. The NEAT1/ARID3A/let-7 axis regulates macrophage polarization and PRRSV replication.\",\n      \"method\": \"EMSA, ChIP, luciferase reporter assay, RNA immunoprecipitation, miRNA sequencing, in vitro and in vivo PRRSV infection models\",\n      \"journal\": \"PLoS pathogens\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — EMSA and ChIP validate direct promoter binding; multiple mechanistic nodes confirmed; single lab porcine model\",\n      \"pmids\": [\"36215225\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Bright/ARID3a increases immunoglobulin heavy chain transcription three- to sevenfold in antigen-activated B cells. It interacts with DNA through the ARID (A/T-rich interaction domain) and associates with nuclear matrix proteins sp100 and LYSp100B, suggesting it may affect chromatin configuration and nuclear sublocalization. Bruton's tyrosine kinase (Btk) is required for Bright DNA binding activity.\",\n      \"method\": \"Transcription reporter assays, ARID domain DNA-binding assays, co-immunoprecipitation with sp100/LYSp100B, Btk requirement for DNA binding activity\",\n      \"journal\": \"Immunologic research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — review of original experimental data; multiple protein interactions reported but individual experiments not detailed; moderate confidence from multiple observations\",\n      \"pmids\": [\"11594453\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"A non-coding intronic variant in ARID3A (rs2238574) acts as an allele-specific enhancer in myeloid cells to regulate ARID3A expression. Luciferase reporter assay and allele-specific ChIP prioritized rs2238574 as causal; genome editing confirmed its regulatory effect. ARID3A knockdown inhibited myeloid differentiation and activation pathways, while overexpression had the opposite effect, functionally linking ARID3A levels to myeloid cell behavior.\",\n      \"method\": \"Luciferase reporter assay, allele-specific ChIP, CRISPR genome editing, ARID3A knockdown/overexpression in myeloid cells, myeloid differentiation assays\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — luciferase plus allele-specific ChIP plus genome editing plus functional KD/OE; single lab but orthogonal methods\",\n      \"pmids\": [\"36977669\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ARID3A (Bright) is an ARID-domain transcription factor that binds AT-rich DNA motifs as a dimer to activate immunoglobulin heavy-chain transcription via a three-component complex with TFII-I and Btk, promotes trophectoderm and placental development by activating TE-specific genes while repressing pluripotency genes through epigenetic acetylation changes, regulates hematopoietic lineage decisions (B-1 vs. B-2, megakaryocytic differentiation with GATA1/SMAD2/3), suppresses Mertk transcription by direct promoter binding in macrophages to impair efferocytosis, represses PTEN to inhibit ferroptosis in cancer cells, acts downstream of Lin28b/Let-7 to control fetal B lymphopoiesis, and modulates IFN-alpha production in B cells; its activity is post-transcriptionally controlled by miR-125b and miR-574-5p, and nuclear import is regulated by NF-κB signaling.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"ARID3A is an ARID-domain transcription factor that binds AT-rich DNA motifs as a dimer to regulate cell fate decisions across multiple lineages, including B-lymphocyte differentiation, hematopoietic stem cell commitment, trophectoderm specification, and megakaryopoiesis. It activates immunoglobulin heavy-chain transcription through a ternary complex with TFII-I and Bruton's tyrosine kinase (Btk), where Btk-mediated phosphorylation of TFII-I is required for transcriptional activity [PMID:16738337, PMID:11594453], and it functions downstream of the Lin28b/Let-7 axis to specify fetal B-1 lymphopoiesis [PMID:25753579]. ARID3A acts as both a transcriptional activator and repressor depending on context: it directly activates trophectoderm genes while repressing pluripotency genes through differential histone acetylation [PMID:25319825], cooperates with p53 to activate p21WAF1 after DNA damage [PMID:22172947], represses Mertk transcription in macrophages to limit efferocytosis [PMID:37659731], and represses PTEN to inhibit ferroptosis in cancer cells [PMID:38781729]. Its expression is post-transcriptionally controlled by miR-125b and Let-7, and its nuclear import is regulated by NF-κB signaling; miR-125b-mediated repression of ARID3A synergizes with GATA1s mutations to drive acute megakaryoblastic leukemia [PMID:34570885, PMID:22469780, PMID:36215225].\",\n  \"teleology\": [\n    {\n      \"year\": 2001,\n      \"claim\": \"Establishing that ARID3A/Bright is a sequence-specific transcription factor that activates immunoglobulin heavy-chain transcription in B cells, binds AT-rich DNA via the ARID domain, associates with nuclear matrix proteins, and requires Btk for DNA binding activity answered the foundational question of how IgH locus accessibility is regulated.\",\n      \"evidence\": \"Transcription reporter assays, DNA binding assays, Co-IP with sp100/LYSp100B, Btk dependence in B cells\",\n      \"pmids\": [\"11594453\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab review of earlier data; individual experiments not independently detailed\", \"Structural basis of ARID domain–DNA interaction unresolved\", \"Mechanism by which Btk enables DNA binding not defined\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Demonstrating that the Xenopus ARID3A ortholog is specifically required for TGF-β but not FGF-mediated mesoderm induction established ARID3A as a pathway-selective mediator of TGF-β/SMAD signaling during embryonic development.\",\n      \"evidence\": \"Morpholino knockdown, engrailed-Dril1 fusions, animal cap assays, and mRNA rescue in Xenopus tropicalis\",\n      \"pmids\": [\"15680369\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mammalian relevance of TGF-β selectivity not directly tested\", \"Biochemical mechanism linking ARID3A to SMAD complexes not defined in this system\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Identifying a three-component Bright/TFII-I/Btk complex and showing that Btk-dependent TFII-I phosphorylation is essential for Bright-driven IgH transcription resolved how ARID3A integrates signaling input with transcriptional activation at the IgH locus.\",\n      \"evidence\": \"Co-immunoprecipitation, domain mapping, IgH reporter assays, and siRNA knockdown in B-cell lines\",\n      \"pmids\": [\"16738337\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether the ternary complex operates at endogenous chromatin genome-wide was untested\", \"Stoichiometry and structural details of the complex unknown\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Discovery that Id1 directly binds ARID3A/Dril1 and inhibits its DNA binding revealed a mechanism by which Id proteins suppress profibrotic gene activation downstream of TGF-β1.\",\n      \"evidence\": \"Protein interaction screen, Co-IP, co-localization, DNA binding assays, TGF-β1 target gene assays, Id1 KO mouse bleomycin model\",\n      \"pmids\": [\"18583319\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab finding; reciprocal validation limited\", \"Whether Id1 inhibition of ARID3A generalizes beyond fibrosis context unknown\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Showing that ARID3A loss in somatic cells induced pluripotency gene expression and multilineage differentiation capacity fundamentally reframed ARID3A from an immunoglobulin-specific factor to a broad repressor of developmental plasticity.\",\n      \"evidence\": \"Knockout mouse models, siRNA knockdown, colony formation, multi-lineage differentiation, gene expression profiling\",\n      \"pmids\": [\"20680960\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Epigenetic mechanism of pluripotency repression was not defined\", \"Whether ARID3A loss achieves bona fide iPSC-equivalent reprogramming was unclear\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Two discoveries in 2011 expanded ARID3A's mechanistic repertoire: cooperation with p53 to activate p21WAF1 at AT-rich promoter elements after DNA damage, and identification of ARID3C as a co-activating partner at IgH loci, revealed context-dependent transcriptional partnerships.\",\n      \"evidence\": \"ChIP, in vitro binding, reporter assays, siRNA in p53-positive/null lines (p21 study); Co-IP, DNA binding, IgH reporters, SUMO assays (ARID3C study)\",\n      \"pmids\": [\"22172947\", \"21955986\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Genome-wide overlap of ARID3A and p53 co-regulation sites not mapped\", \"ARID3C contribution relative to ARID3A at endogenous loci untested\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Demonstrating that miR-125b directly targets ARID3A to block B-cell progenitor differentiation while conferring survival advantage established a post-transcriptional regulatory axis controlling ARID3A levels in hematopoiesis.\",\n      \"evidence\": \"3′UTR luciferase reporter, miR-125b overexpression/inhibition, ARID3A siRNA, proliferation and apoptosis assays in murine and human leukemic B-cell lines\",\n      \"pmids\": [\"22469780\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo physiological relevance of miR-125b–ARID3A axis in normal B-cell development not directly shown here\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Two parallel 2014 studies established ARID3A as a master regulator of early embryonic and hematopoietic lineage decisions: it drives trophectoderm specification upstream of Cdx2 via differential histone acetylation, and controls B-1 versus B-2 lineage allocation and chromatin accessibility at IgH enhancers.\",\n      \"evidence\": \"ARID3A KO mouse with placental defects, ES cell OE/KD, ChIP, histone acetylation assays (TE study); transgenic/KO mice, B cell subset flow cytometry, DNA binding assays (hematopoiesis study)\",\n      \"pmids\": [\"25319825\", \"24678314\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct ARID3A target genes in trophoblast beyond a few markers not comprehensively defined\", \"Mechanism by which ARID3A opens chromatin at IgH enhancer molecularly unclear\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Placing ARID3A downstream of the Lin28b/Let-7 axis and showing its sufficiency to reprogram adult pro-B cells toward B-1 fate resolved a key step in the fetal-to-adult B lymphopoiesis switch and explained how a single transcription factor coordinates developmental timing with lineage output.\",\n      \"evidence\": \"Retroviral transduction of ARID3A/Lin28b in adult BM progenitors, Let-7 modulation, ARID3A KD in fetal pro-B cells, transplantation, VH repertoire analysis\",\n      \"pmids\": [\"25753579\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct transcriptional targets of ARID3A that enforce B-1 identity not identified\", \"Whether ARID3A acts through chromatin remodeling or direct gene activation in this context unknown\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Demonstrating that ARID3A knockdown in human cord blood HSCs shifted lineage output from B-lymphoid toward myeloid confirmed ARID3A as a conserved regulator of human multilineage hematopoietic decisions.\",\n      \"evidence\": \"Lentiviral KD and OE of ARID3A in cord blood CD34+ HSCs, in vitro differentiation, flow cytometry, transcription factor expression analysis\",\n      \"pmids\": [\"26685208\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vitro system only; in vivo human HSC repopulation not tested\", \"Downstream transcriptional programs mediating lineage bias not comprehensively mapped\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Identifying ARID3A+ B cells as IFN-α producers following TLR9 stimulation linked ARID3A to innate immune effector function and inflammatory amplification relevant to SLE pathogenesis.\",\n      \"evidence\": \"ARID3a+ B cell sorting, CpG stimulation, IFN-α ELISA, co-culture with plasmacytoid dendritic cells\",\n      \"pmids\": [\"27522115\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether ARID3A directly regulates IFN-α gene transcription or acts indirectly is unknown\", \"Causal role of ARID3A in SLE not established by genetic evidence\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Validation that miR-574-5p directly targets ARID3A and modulates cardiac fibroblast-to-myofibroblast differentiation revealed a second miRNA axis regulating ARID3A levels in a non-hematopoietic, TGF-β-driven fibrotic context.\",\n      \"evidence\": \"3′UTR luciferase reporter, miR-574-5p OE/silencing, ARID3A KD in human cardiac fibroblasts\",\n      \"pmids\": [\"31672272\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab study; limited to in vitro cardiac fibroblast system\", \"Whether ARID3A promotes or opposes fibrotic gene programs in this context appears opposite to the Id1 study — contradiction unresolved\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Three 2022 studies expanded ARID3A's mechanism: (1) miR-125b repression of ARID3A cooperates with GATA1s to block megakaryocytic differentiation and drive AMKL, with ARID3A forming a complex with SMAD2/3; (2) ARID3A partners with CEP131 to activate KDM3A transcription, promoting cancer stemness via H3K9me2 demethylation; (3) ARID3A directly binds the let-7 gene cluster promoter to repress let-7 in macrophages, regulated by NF-κB-controlled nuclear import.\",\n      \"evidence\": \"Forward/reverse genetics and PDX rescue (AMKL); Co-IP, CUT&Tag, H3K9me2 ChIP (liver cancer); EMSA, ChIP, RIP, PRRSV infection models (macrophage/let-7)\",\n      \"pmids\": [\"34570885\", \"36008383\", \"36215225\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"SMAD2/3–ARID3A complex composition and DNA targets not genome-wide mapped\", \"CEP131–ARID3A interaction awaits independent replication\", \"NF-κB–ARID3A nuclear import mechanism molecularly undefined\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Two 2023 findings revealed ARID3A as a direct transcriptional repressor of Mertk in macrophages limiting efferocytosis, and identified a non-coding enhancer variant (rs2238574) that modulates ARID3A expression to control myeloid differentiation, connecting genetic regulation of ARID3A levels to myeloid functional output.\",\n      \"evidence\": \"Myeloid-specific KO mouse, ChIP-seq, reporter assays, Mertk inhibitor rescue in vivo (Mertk study); CRISPR editing, allele-specific ChIP, luciferase, KD/OE in myeloid cells (enhancer study)\",\n      \"pmids\": [\"37659731\", \"36977669\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Additional direct ARID3A-repressed targets in macrophages beyond Mertk not mapped\", \"rs2238574 functional impact on disease susceptibility in patient cohorts not established\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Demonstrating that ARID3A directly represses PTEN transcription to sustain GPX4 and inhibit ferroptosis revealed a novel ARID3A–PTEN–ferroptosis axis mediating chemoresistance in pancreatic cancer.\",\n      \"evidence\": \"CUT&Tag, RNA-seq, ARID3A KD/OE, lipid peroxidation assays, GPX4/PTEN Western blots, in vivo tumor models, gemcitabine sensitivity assays\",\n      \"pmids\": [\"38781729\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab study; PTEN repression mechanism (cofactors, chromatin changes) not detailed\", \"Generalizability beyond pancreatic cancer untested\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Major unresolved questions include the structural basis of ARID3A dimerization and DNA recognition, the genome-wide chromatin landscape it occupies across cell types, the molecular mechanism by which NF-κB controls its nuclear import, and how its activating versus repressive functions are contextually switched.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No crystal or cryo-EM structure of ARID3A or its complexes\", \"No unified genome-wide binding map across hematopoietic, trophoblast, and cancer contexts\", \"Molecular basis for context-dependent activation versus repression unresolved\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [0, 2, 5, 6, 10, 14, 17, 18]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 2, 5, 13, 14, 15, 17]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [2, 5, 17, 18]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": []},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [0, 2, 5, 13, 14, 15, 17]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [7, 8, 9]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [5, 7, 11]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [11, 12, 17]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [4, 12, 15]}\n    ],\n    \"complexes\": [\n      \"Bright/TFII-I/Btk complex\",\n      \"ARID3A/SMAD2/3 complex\",\n      \"ARID3A/CEP131 complex\"\n    ],\n    \"partners\": [\n      \"GTF2I\",\n      \"BTK\",\n      \"ARID3C\",\n      \"SMAD2\",\n      \"SMAD3\",\n      \"CEP131\",\n      \"ID1\",\n      \"TP53\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}